Open AccessComparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn’s Disease
Author(s) -
Yiyoung Kwon,
Ben Kang,
Eun Sil Kim,
Yon Ho Choe,
Mi Jin Kim
Publication year - 2022
Publication title -
therapeutic drug monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 93
eISSN - 1536-3694
pISSN - 0163-4356
DOI - 10.1097/ftd.0000000000000976
Subject(s) - ustekinumab , medicine , trough (economics) , crohn's disease , gastroenterology , trough concentration , erythrocyte sedimentation rate , faecal calprotectin , infliximab , calprotectin , pharmacokinetics , disease , inflammatory bowel disease , economics , macroeconomics
Ustekinumab is a recently introduced biological agent for the treatment of Crohn's disease. The clinical use of the trough concentration of ustekinumab is not as standardized as that of infliximab. The authors aimed to introduce a measurement method and the results of trough concentrations of ustekinumab in clinical applications.